StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO – Free Report) (TSE:APS) in a report published on Saturday. The firm issued a hold rating on the biotechnology company’s stock.
Several other research firms have also recently weighed in on APTO. HC Wainwright reaffirmed a buy rating and set a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, June 14th. Canaccord Genuity Group decreased their price target on shares of Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a research note on Thursday, May 16th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $14.80.
Get Our Latest Analysis on Aptose Biosciences
Aptose Biosciences Stock Performance
Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.15. On average, sell-side analysts forecast that Aptose Biosciences will post -2.62 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent filing with the SEC. Hedge funds and other institutional investors own 26.62% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Articles
- Five stocks we like better than Aptose Biosciences
- The How and Why of Investing in Gold Stocks
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- How to Calculate Return on Investment (ROI)
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Technology Stocks Explained: Here’s What to Know About Tech
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.